Prolonged cardioprotective effect of pyridostigmine encapsulated in liposomes

Life Sciences

Volumn 86, Issue 1-2, 2010, Pages 17-23

  Vidal, Alessandra Teixeira ^a   Guimarães, Homero Nogueira ^b   de Paula, Danielle Cristiane Correa ^a   Frezard, Frederic ^b   Silva Barcellos, Neila Márcia ^a   Grabe Guimarães, Andrea ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Liposomes; Pyridostigmine; QT interval,ECG; Rats; Sympathetic stimulation

Indexed keywords

LIPOSOME; NORADRENALIN; PYRIDOSTIGMINE; ADRENERGIC RECEPTOR STIMULATING AGENT; CARDIOTONIC AGENT;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG FORMULATION; ELECTROCARDIOGRAM; ENCAPSULATION; FREEZE THAWING; HEART PROTECTION; HEART RATE; MALE; NONHUMAN; PARTICLE SIZE; PELLET EXTRUSION; PR INTERVAL; Q WAVE; QRS COMPLEX; QT INTERVAL; RAT; RR INTERVAL; SYSTOLIC BLOOD PRESSURE; T WAVE; WISTAR RAT; ZETA POTENTIAL; ANIMAL; BLOOD PRESSURE; CHEMISTRY; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; TIME;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; ARRHYTHMIAS, CARDIAC; BLOOD PRESSURE; CARDIOTONIC AGENTS; ELECTROCARDIOGRAPHY; HEART RATE; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; NOREPINEPHRINE; PARTICLE SIZE; PYRIDOSTIGMINE BROMIDE; RATS; RATS, WISTAR; SYMPATHOMIMETICS; TIME FACTORS;

EID: 77449136117     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.10.011     Document Type: Article

References (67)

1. Abernethy DR, Wesche DL, Barbey JT, Ohrt C, Mohanty S, Pezzullo JC, Schuster BG. Stereoselective halofantrine disposition an effect: concentration-related QTc prolongation. British Journal of Pharmacology 51 (3), 231-237, 2001.
2. Ahnve S. Is QT interval prolongation a strong or weak predictor for cardiac death? Circulation 84 (4), 1862-1865, 1991.
3. Ahnve S, Vallin H. Influence of heart rate and inhibition of autonomic tone on the QT interval. Circulation 65 (3), 435-439, 1982.
4. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 83 (6), 1888-1894, 1991.
5. Androne AS, Hryniewicz K, Goldsmith R, Arwady A, Katz SD. Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure. Heart 89 (8), 854-858, 2003.
6. Aquilonius SM, Eckernäs SÅ, Hartvig P, Lindström B, Osterman PO. Pharmacokinetics and oral bioavailability of pyridostigmine in man. European Journal of Clinical Pharmacology 18 (5), 423-428, 1980.
7. Bazett HC. An analysis of the time-relations of the electrocardiogram. Heart 7, 353-370, 1920.
8. Bernátová I, Babál P, Grubbs RD, Morris M. Acetylcholinesterase inhibition affects cardiovascular structure in mice. Physiology Research 55 (Suppl 1), S89-S97, 2006.
9. Browne KF, Zipes DP, Heger JJ, Prystowsky EN. Influence of the autonomic nervous system on the QT interval in man. The American Journal of Cardiology 50 (5), 1099-1103, 1982.
10. Casadei B, Conway J, Forfar C, Sleight P. Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure. Heart 75 (3), 274-280, 1996.
11. Castro RRT, Serra SM, Nóbrega ACL. Reduction of Qtc interval dispersion. Potential mechanism of cardiac protection of pyridostigmine bromide. Arquivos Brasileiros de Cardiologia 75 (3), 210-213, 2000.
12. Castro RTT, Porphirio G, Serra SM, Nóbrega ACL. Cholinergic stimulation with pyridostigmine reduces the QTc interval in coronary artery disease. Brazilian Journal of Medical and Biological Research 35 (6), 685-689, 2002.
13. Castro RRT, Porphirio G, Serra SM, Nóbrega ACL. Cholinergic stimulation with pyridostigmine protects against exercise induced myocardial ischaemia. Heart 90 (10), 1119-1123, 2004.
14. Castro RTT, Serra SM, Porphirio G, Mendes F, Oliveira L, Nóbrega A. Pyridostigmine reduces QTc interval during recovery from maximal exercise in ischemic heart disease. International Journal of Cardiology 107 (1), 138-139, 2006.
15. Catelli M, Feldman J, Bousquet P, Tibiriçá E. Protective effects of centrally acting sympathomodulatory drugs on myocardial ischemia induced by sympathetic overactivity in rabbits. Brazilian Journal of Medical and Biological Research 36 (1), 85-95, 2003.
16. De Ferrari GM, Vanoli E, Curcuruto P, Tommasini G. Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine. American Heart Journal 124 (4), 883-890, 1992.
17. De Ferrari GM, Salvati P, Grossoni M, Ukmar G, Vaga L, Patrono C, Schwartz PJ. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. Journal of the American College of Cardiology 22 (1), 283-290, 1993.
18. Dubovicky M, Paton S, Morris M, Mach M, Lucot JB. Effects of combined exposure to pyridostigmine bromide and shaker stress on acoustic startle response, pre-pulse inhibition and open field behavior in mice. Journal of Applied Toxicology 27 (3), 276-283, 2007.
19. Dunlap ME, Bibevski S, Rosenberry TL, Ernsberger P. Mechanisms of altered vagal control in heart failure: Influence of muscarinic receptors and acetylcholinesterase activity. American Journal of Physiology - Heart and Circulatory Physiology 285 (4), H1632-H1640, 2003.
20. Francis G. Modulation of peripheral sympathetic nerve transmission. Journal of the American College of Cardiology 12, 250-254, 1988.
21. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Medica Scandinavica 53, 469-486, 1920.
22. Goldstein RE, Beiser GD, Stampfer M, Epstein SE. Impairment of autonomically mediated heart rate control in patients with cardiac dysfunction. Circulation Research 36 (5), 571-578, 1975.
23. Grabe-Guimarães A,AlvesLM, Tibiriçá E,Nóbrega ACL. Pyridostigmine blunts the increases in myocardial oxygen demand elicited by the stimulation of the central nervous system in anesthetized rats. Clinical Autonomic Research 9 (2), 83-89, 1999.
24. Hayano T, Shimizu A, Ikeda Y, Yamamoto T, Yamagata T, Ueyama T, Furutani Y, Matsuzaki M. Paradoxical effects of pirenzepine on parasympathetic activity in chronic heart failure and control. International Journal of Cardiology 68 (1), 47-56, 1999.
25. Hayes E, Pugsley MK, Penz WP, Adaikan G, Walker MJA. Relationship between QaT and RR intervals in rats, guinea pigs, rabbits, and primates. Journal of Pharmacological and Toxicological Methods 32 (4), 201-207, 1994.
26. Hegazy N, Demirel M, Yazan Y. Preparation and in vitro evaluation of pyridostigmine bromide microparticles. International Journal of Pharmaceutics 242 (1-2), 171-174, 2002.
27. Henning RJ, Khalil IR, Levy MN. Vagal stimulation attenuates sympathetic enhancement of left ventricular function. American Journal of Physiology - Heart and Circulatory Physiology 258 (5), H1470-H1475, 1990.
28. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. The American Journal of Cardiology 80 (9B), 35J-39J, 1997.
29. Hodges M. Rate correction of the QT interval. Cardiac Electrophysiology Review 1 (3), 360-363, 1997.
30. Hoyer D, Maestrib R, La Rovere MT, Pinna GD. Autonomic response to cardiac dysfunction in chronic heart failure: a risk predictor based on autonomic information flow. Pacing and Clinical Electrophysiology 31 (2), 214-220, 2008.
31. Indik JH, Pearson EC, Fried K, Woosley RL. Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval. Heart Rhythm 3 (9), 1003-1007, 2006.
32. Klibanov AL, Maruyamal K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Letters 268 (1), 235-237, 1990.
33. Kluwe WM, Page JG, Toft JD, Ridder WE, Chung H. Pharmacological and toxicological evaluation of orally administered pyridostigmine in dogs. Toxicological Sciences 14 (1), 40-53, 1989.
34. Koga T, Kuwano K, Kito G, Kanefuji K. Evaluation of QT interval using a linear model in individual cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods 55 (3), 265-270, 2007.
35. Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease. Physiological basis and prognostic implications. Journal of the American College of Cardiology 51 (18), 1725-1733, 2008.
36. Leite EA, Grabe-Guimarães A, Guimarães HN, Machado-Coelho GLL, Barratt G, Mosqueira VCF. Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices. Life Sciences 80 (14), 1327-1334, 2007.
37. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109 (1), 120-124, 2004.
38. London B, Jerona A, Zhou J, Buckett P, Han X, Mitchell GF, Koren G. Long QT and ventricular arrhythmias in transgenic mice expressing the N terminus and first transmembrane segment of a voltage-gated potassium channel. Proceedings of the National Academy of Sciences 95 (6), 2926-2931, 1998.
39. Lukyanov AN, Hartner WC, Torchilin VP. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. Journal of Controlled Release 94 (1), 187-193, 2004.
40. Magnano AR, Holleran S, Ramakrishnan R, Reiffel JA, Bloomfield DM. Autonomic nervous system influences on QT interval in normal subjects. Journal of the American College of Cardiology 39 (11), 1820-1826, 2002.
41. Malik M, Farbom P, Camm AJ, Hnatkova K, Batchvarov V. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart 87 (3), 220-228, 2002.
42. Nayar R, Hope MJ, Cullis PR. Generation of large unilamellar vesicles from long-chain saturated phosphatidylcholines by extrusion technique. Biochimica et Biophysica Acta 986, 200-206, 1989.
43. Nóbrega ACL, Carvalho ACG, Bastos BG. Resting and reflex heart rate response during cholinergic stimulation with pyridostigmine in humans. Brazilian Journal of Medical and Biological Research 29 (11), 1461-1465, 1996.
44. Nóbrega ACL, Carvalho ACG, Santos KB, Soares PPS. Pyridostigmine blunts the cardiac response to mental stress. Clinical Autonomic Research 9 (1), 11-16, 1999.
45. Nóbrega ACL, Loures DL, Pontes PV, Sant'Anna ID, Mesquita ET. Cholinergic stimulation with pyridostigmine prevents the impairment in ventricular function during mental stress in coronary artery disease patients. International Journal of Cardiology 125 (3), 418-421, 2008.
46. Osterziel KJ, Dietz R. Improvement of vagal tone by ACE inhibition: a mechanism of cardioprotection in patients with mild-to-moderate heart failure. Journal of Cardiovascular Pharmacology 27 (Suppl 2), 25-30, 1996.
47. Padley JR, Overstreet DH, Pilowsky PM, Goodchild AK. Impaired cardiac and sympathetic autonomic control in rats differing in acetylcholine receptor sensitivity. American Journal of Physiology - Heart and Circulatory Physiology 289 (5),H1985-H1992, 2005.
48. Pontes PV, Bastos BG, Romêo FLJM, Mesquita ET, Nóbrega ACL. Cholinergic stimulation with pyridostigmine in healthy subjects, hemodynamic and echocardiographic analysis. Arquivos Brasileiros de Cardiologia 72 (3), 302-306, 1999.
49. Porter TM, Eckberg DL, Fritsch JM, Rea RF, Beightol LA, Schmedtje Jr JF, Mohanty PK. Autonomic pathophysiology in heart failure patients: sympathetic-cholinergic interrelations. Journal of Clinical Investigation 85 (5), 1362-1371, 1990.
50. Puddu PE, Jouve R, Mariotti S, Giampaoli S, Lanti M, Reale A, Menotti A. Evaluation of 10 QT prediction formulas in 881 middle-aged men from the seven countries study: emphasis on the cubic root Fridericia's equation. Journal of Electrocardiology 21 (3), 219-229, 1988.
51. Sant'anna ID, Sousa EB, Moraes AA, Loures DL, Mesquita ET, Nóbrega ACL. Cardiac function during mental stress: cholinergic modulation with pyridostigmine in healthy subjects. Clinical Science 105 (2), 161-165, 2003.
52. Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbroucke JP, Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 84 (4), 1516-1523, 1991.
53. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 57 (6), 1074-1077, 1978.
54. Serra SM, Costa RV, Castro RRT, Xavier SS, Nóbrega ACL. Cholinergic stimulation improves autonomic and hemodynamic profile during dynamic exercise in patients with heart failure. Journal of Cardiac Failure 15 (2), 124-129, 2009.
55. Simonson E, Cady LD, Woodbury M. The normal Q-T interval. American Heart Journal 63 (6), 747-753, 1962.
56. Singer W, Opfer-Gehrking TL, Nickander KK, Hines SM, Low PA. Acetylcholinesterase inhibition in patients with orthostatic intolerance. Journal of Clinical Neurophysiology 23 (5), 477-482, 2006.
57. Soares PPS, Nóbrega ACL, Ushizima MR, Irigoyen MCC. Cholinergic stimulation with pyridostigmine increases heart rate variability and baroreflex sensitivity in rats. Autonomic Neuroscience 113 (1-2), 24-31, 2004.
58. Soares PPS, Porto CS, Abdalla FMF, Fuente RN, Moreira ED, Krieger EM, Irigoyen MCC. Effects of rat sinoaortic denervation on the vagal responsiveness and expression of muscarinic acetylcholine receptors. Journal of Cardiovascular Pharmacology 47 (3), 331-336, 2006.
59. Taggart P, Sutton P, Chalabi Z, Boyett MR, Simon R, Elliott D, Gill JS. Effect of adrenergic stimulation on action potential duration restitution in humans. Circulation 107 (2), 285-289, 2003.
60. Tai CT, Chiou CW, Chen SA. Interaction between the autonomic nervous system and atrial tachyarrhythmias. Journal of Cardiovascular Electrophysiology 13 (1), 83-87, 2002.
61. Takahama H, Minamino T, Asanuma H, Fujita M, Asai T, Wakeno M, Sasaki H, Kikuchi H, Hashimoto K, Oku N, Asakura M, Kim J, Takashima S, Komamura K, Sugimachi M, Mochizuki N, Kitakaze N. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. Journal of the American College of Cardiology 53 (8), 709-717, 2009.
62. Torchilin VP. Targeting of drugs and drug carriers within the cardiovascular system. Advanced Drug Delivery Reviews 17 (1), 75-101, 1995.
63. Torchilin VP, Klibanov AL, Huang L, SO'Donnell, Nossiff ND, Khaw BA. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. The FASEB Journal 6 (9), 2716-2719, 1992.
64. Venkatesh G, Fallen EL, Kamath MV, Connolly S, Yusuf S. Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure. Heart 76 (2), 137-143, 1996.
65. Verma DD, Hartner WC, Levchenko TS, Bernstein EA, Torchilin VP. ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharmaceutical Research 22 (12), 2115-2120, 2005.
66. Zamotrinsky AV, Kondratiev B, De Jong JW. Vagal neurostimulation in patients with coronary artery disease. Autonomic Neuroscience: Basic and Clinical 88 (1-2), 109-116, 2001.
67. Zuanetti G, De Ferrari GM, Priori SG, Schwartz PJ. Protective effect of vagal stimulation on reperfusion arrhythmias in cats. Circulation Research 61 (3), 429-435, 1987.